Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with <i>BIM</i> deletion polymorphism relapsed after stop imatinib
-
- KATAGIRI Seiichiro
- Department of Hematology, Tokyo Medical University
-
- TAUCHI Tetsuzo
- Department of Hematology, Tokyo Medical University
-
- UMEZU Tomohiro
- Department of Molecular Oncology, Institute of Medical Science, Tokyo Medical University
-
- SAITO Yuu
- Department of Hematology, Tokyo Medical University
-
- SUGURO Tamiko
- Department of Hematology, Tokyo Medical University
-
- ASANO Michiyo
- Department of Hematology, Tokyo Medical University
-
- YOSHIZAWA Seiichiro
- Department of Hematology, Tokyo Medical University
-
- KITAHARA Toshihiko
- Department of Hematology, Tokyo Medical University
-
- AKAHANE Daigo
- Department of Hematology, Tokyo Medical University
-
- TANAKA Yuko
- Department of Hematology, Tokyo Medical University
-
- FUJIMOTO Hiroaki
- Department of Hematology, Tokyo Medical University
-
- OKABE Seiichi
- Department of Hematology, Tokyo Medical University
-
- GOTOH Moritaka
- Department of Hematology, Tokyo Medical University
-
- ITO Yoshikazu
- Department of Hematology, Tokyo Medical University
-
- OHYASHIKI Junko H.
- Department of Molecular Oncology, Institute of Medical Science, Tokyo Medical University
-
- OHYASHIKI Kazuma
- Department of Hematology, Tokyo Medical University
Bibliographic Information
- Other Title
-
- Imatinib中止後の再発にimatinibとIFNα併用療法を行い無治療で分子寛解を維持する<i>BIM</i>欠失多型のCML
- 症例報告 第1回日本血液学会関東甲信越地方会 会長推薦演題 Imatinib中止後の再発にimatinibとIFNα併用療法を行い無治療で分子寛解を維持するBIM欠失多型のCML
- ショウレイ ホウコク ダイ1カイ ニホン ケツエキ ガッカイ カントウ コウシンエツチホウカイ カイチョウ スイセン エンダイ Imatinib チュウシ ゴ ノ サイハツ ニ imatinib ト IFNaヘイヨウ リョウホウ オ オコナイ ムチリョウ デ ブンシカンカイ オ イジ スル BIM ケツシツタケイ ノ CML
Search this article
Abstract
A 51-year-old man with chronic myeloid leukemia (CML) was treated with imatinib (IM). After 24 months of treatment, he achieved a complete molecular response (CMR), which he sustained for 3 years. However, 4 months after discontinuing IM treatment, the CML relapsed. The patient was treated again with IM and achieved CMR. A combination of IM and interferon-α (IFNα) was administered for the following year, and then discontinued. The patient has since sustained CMR without therapy for 24 months, to date. This patient was found to have a BCL2L11 (BIM) deletion polymorphism. CML patients with a BIM deletion polymorphism show a low response to IM, and we infer that the BIM deletion polymorphism is a negative factor for discontinuation of IM. IFNα treatment is expected to prevent relapse during immunological surveillance. Therefore, the combination of IM and IFNα might be a feasible approach for CML patients who experience difficulty with IM discontinuation.
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 56 (2), 216-219, 2015
The Japanese Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1390282680014041600
-
- NII Article ID
- 130004920704
-
- NII Book ID
- AN00252940
-
- ISSN
- 18820824
- 04851439
-
- NDL BIB ID
- 026217772
-
- PubMed
- 25765803
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- PubMed
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed